Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 02, 2026
TickeronGET DAILY SIGNALS
Why Is Integra LifeSciences Holdings (IART) Stock Down -15.48% Today?

Why Is Integra LifeSciences Holdings (IART) Stock Down -15.48% Today?

Key Takeaways

  • Shares of Integra LifeSciences Holdings (IART) fell roughly 15.5% in early trading, dropping from a prior close of $16.09 to about $13.60.
  • The sell-off followed a cut to full-year 2026 revenue and adjusted earnings guidance tied to July flooding at its Cincinnati manufacturing facility.
  • Preliminary third-quarter results came in below expectations, with adjusted EPS of $0.55–$0.59 on revenue of approximately $410–$412 million.
  • The company now expects the flood to reduce fourth-quarter revenue by an additional $15–$20 million, with full manufacturing recovery not expected until the second quarter of 2027.
  • Offsetting factors include anticipated insurance recoveries and strong operating cash flow of roughly $190–$200 million for the year.

Opening Summary

Integra LifeSciences Holdings Corporation (IART), a global medical technology company focused on neurosurgery, tissue reconstruction, and specialty surgical products, saw its stock plunge in Friday's session after cutting its full-year 2026 outlook. The shares traded near $13.60, down about 15.5% from the prior session's close of $16.09. The market reaction was driven by preliminary third-quarter results and revised guidance that reflected the ongoing impact of July's flooding at the company's Cincinnati facility.

Guidance Cut Following Cincinnati Facility Flooding

The primary catalyst behind the decline was a downward revision to Integra's full-year financial targets. The company now projects adjusted earnings of $2.30 to $2.40 per share on revenue of $1.634 billion to $1.654 billion, down from its previous guidance of $2.40 to $2.50 per share on revenue of $1.654 billion to $1.695 billion.

The revision stems largely from the July flooding event that damaged portions of the Cincinnati site, including equipment and inventory, and disrupted production of several products within the Specialty Surgical Technologies portfolio. Management estimates the supply disruption reduced third-quarter revenue by approximately $7 million and will reduce fourth-quarter revenue by an additional $15 million to $20 million. A full return to manufacturing operations at the site is not expected until the second quarter of 2027.

Preliminary Third-Quarter Results Fall Short

Alongside the guidance update, Integra provided unaudited preliminary third-quarter results. The company expects adjusted earnings per diluted share of $0.55 to $0.59 on revenue of approximately $410 million to $412 million. The revenue figure came in below what Wall Street had anticipated, adding to investor concerns that the flooding's operational toll will extend well into the coming quarters.

While management emphasized progress in executing business continuity and recovery plans—including use of available inventory and alternate supply sources—the extended recovery timeline weighed on sentiment. Shares responded with an earnings-driven move lower as investors recalibrated expectations for the remainder of the year.

Cash Flow and Insurance Offsets

The sell-off occurred despite several mitigating factors highlighted by the company. Integra expects strong cash generation, including more than $85 million of operating cash flow in the third quarter and approximately $190 million to $200 million for the full year. Additionally, the company maintains property and business interruption insurance covering the Cincinnati facility and expects insurance recoveries to mitigate a substantial portion of the earnings impact through the recovery period.

Separately, Integra announced the launch of a proposed $600 million seven-year senior secured term loan intended to refinance existing indebtedness, extend maturities, and maintain financial flexibility. While this refinancing supports the company's balance sheet, it did not offset the negative reaction to the weaker operational outlook.

Market Context and Trading Activity

The sharp decline in IART reflected a company-specific catalyst rather than broad market weakness, as investors repriced the stock based on the downwardly revised guidance and a slower-than-hoped recovery timeline. The magnitude of the move indicates elevated selling pressure and heavier-than-normal trading activity relative to the stock's recent daily volumes.

The drop broke through several recent trading levels, pushing the shares well below the $15–$16 range where they had consolidated over the prior week. The move underscores how sensitive the stock remains to operational disruptions at its manufacturing sites and to any revision in forward guidance.

What Comes Next for IART

Investors will now focus on the company's formal third-quarter earnings report and conference call, expected later in October, for additional detail on the recovery timeline and any updates to insurance claims. Key watch points include the pace of production ramp at the Cincinnati facility, the impact on product availability across the Specialty Surgical Technologies portfolio, and whether insurance recoveries materialize as management expects.

Risks remain tilted to the downside, including the possibility of further disruptions, unforeseen recovery costs, and the potential for analyst estimates to be revised lower in response to the reduced guidance. At the same time, the company's strong cash flow outlook and progress on debt refinancing provide a degree of financial cushion as it works through the operational recovery.

Trending AI Robots

Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to explore. To discover which AI-driven strategies are currently leading the market, visit the Trending AI Robots page today.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IART

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


IART in downward trend: 10-day moving average moved below 50-day moving average on November 18, 2026

The 10-day moving average for IART crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IART as a result. In 68 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

The Moving Average Convergence Divergence Histogram (MACD) for IART turned negative on November 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 33 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.

IART moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for IART moved below the 200-day moving average on November 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IART declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

IART broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IART entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IART's RSI Oscillator exited the oversold zone, 25 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +2.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where IART advanced for three days, in 183 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.000) is normal, around the industry mean (4.142). IART has a moderately low P/E Ratio (-149.111) as compared to the industry average of (3.291). Projected Growth (PEG Ratio) (0.669) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.751) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. IART’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IART’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of medical devices, implants and biomaterials

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1100 Campus Road
Phone
+1 609 275-0500
Employees
4427
Web
https://www.integralife.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.